Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population?based study

Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of new malignancies. However, limited data been published about the impact CLL treatment on this risk. Here we followed a Danish population-based cohort patients for risks in registry (2008–2017) were included. Up to 50 CLL-free matched comparators identified. First-line was categorized into four groups; bendamustine, chlorambucil, fludarabine or other. from diagnosis individual types malignancy. Adjusted hazard ratios (HR) malignancies and 95% confidence intervals (95% CI) calculated. Overall, 4286 214 150 controls developed 594 20 565 respectively. Risk patients. Chemotherapy registered 1064 (25%) CLL. associated HR (1·51, CI: 1·3–1·8) any Specifically, myelodysplastic syndrome (MDS) (HR 4·93, 1·2–19·8). are at other haematological solid compared general population. exposure is second MDS.